Alkem’s Revolutionary therapy TERIPARATIDE-GEMFRAC for weak bones now more accessible to all Indians

In a bid to make osteoporosis treatment affordable to Indian masses, Alkem Laboratories has slashed the price of its Teriparatide brand, Gemfrac.

Until now Teriparatide has been available in India at a monthly cost of therapy ranging from ₹7,000/- to ₹10,000/- limiting accessibility for many patients. Alkem has revised the rate of its Teriparatide brand. Gemfrac to make it available at ₹4,000/- per month, making osteoporosis treatment more affordable and accessible.

This reduction is expected to benefit a broader patient population, improving osteoporosis management in India.

Teriparatide, a recombinant fragment of human parathyroid hormone (N-terminal 34 amino acids), is a powerful osteoanabolic agent. Multiple clinical trials have confirmed its safety and effectiveness in treating osteoporosis.

Alkem Labs Management said, “At Alkem, we believe advanced healthcare should be accessible to all. With Gemfrac, India’s most affordable Teriparatide, we are redefining osteoporosis care by making this gold-standard treatment more affordable for millions. With over 61 million Indians affected by osteoporosis & 80% of which are women, access to effective treatment is crucial. By significantly reducing costs, we aim to improve treatment adherence and reduce fracture risks. This initiative reflects our unwavering commitment to affordable innovation and patient-first healthcare solutions”.